Guselkumab Tremfya IBD — PatSnap Eureka
Guselkumab (Tremfya) in IBD: GALAXI Program, IL-23 Strategy & Competitive Landscape
Janssen's selective IL-23p19 inhibitor guselkumab is under active Phase III investigation in Crohn's disease and ulcerative colitis. Explore the mechanistic rationale, GALAXI trial design, and competitive positioning vs. risankizumab and ustekinumab — powered by PatSnap Eureka intelligence.
Selective IL-23p19 Blockade: Why Specificity Matters in IBD
The IL-23 cytokine pathway plays a central role in driving chronic intestinal inflammation in both Crohn's disease and ulcerative colitis. IL-23 signals through a heterodimeric receptor and promotes the differentiation and survival of Th17 and Th22 cells — key mediators of mucosal injury in inflammatory bowel disease.
Guselkumab (Tremfya), developed by Janssen, is a fully human IgG1λ monoclonal antibody that selectively binds the p19 subunit of IL-23. This is mechanistically distinct from ustekinumab (Stelara), which targets the shared p40 subunit of both IL-12 and IL-23 — meaning ustekinumab simultaneously suppresses IL-12-driven Th1 immunity alongside IL-23-driven Th17 responses.
The selective IL-23p19 approach, shared by guselkumab and risankizumab (Skyrizi, AbbVie), is hypothesised to preserve IL-12-mediated host defence mechanisms while still achieving deep suppression of the pathological IL-23/Th17 axis. This selectivity is the primary mechanistic rationale for the next-generation IL-23 inhibitor class in IBD drug development.
The FDA and EMA have both recognised the IL-23 pathway as a validated therapeutic target in IBD, with regulatory frameworks established through the approval of risankizumab for Crohn's disease — providing a precedent pathway for guselkumab's GALAXI program submissions.
The GALAXI Phase III Program: Crohn's Disease and Ulcerative Colitis
Janssen's GALAXI program represents the pivotal Phase III investigation of guselkumab across both major IBD indications, with clinical endpoints aligned to regulatory expectations for remission and endoscopic response.
GALAXI CD: Phase III Evaluation in Crohn's Disease
The GALAXI Crohn's disease trials evaluate guselkumab's efficacy in achieving clinical remission and endoscopic response in patients with moderately to severely active CD. The program assesses both induction and maintenance phases, consistent with the dual-phase regulatory framework established for biologics in Crohn's disease. Endpoints include clinical remission rates, endoscopic improvement, and patient-reported outcome measures aligned with FDA guidance.
Phase III ActiveGALAXI UC: Expanding the IBD Indication Footprint
The GALAXI ulcerative colitis program investigates guselkumab in patients with moderately to severely active UC. This parallel development strategy — running CD and UC programs simultaneously — mirrors the approach taken by AbbVie with risankizumab and reflects the broader industry recognition that IL-23 inhibition is mechanistically relevant across the IBD spectrum. Regulatory submissions would follow independent data packages for each indication.
Phase III ActiveInduction and Maintenance: Dual-Phase Clinical Architecture
Like other biologics in IBD, the GALAXI program employs a dual-phase design with separate induction and maintenance periods. This architecture is required by regulators including the EMA and FDA for IBD indications and allows assessment of both rapid disease control and durable long-term remission. The design aligns with the clinical development framework used by risankizumab in its approved Crohn's disease program.
Induction + MaintenanceRegulatory Pathway: Building on IL-23 Class Precedent
Risankizumab's approval for Crohn's disease by the FDA and EMA established regulatory precedent for the selective IL-23p19 inhibitor class in IBD. Guselkumab's GALAXI program is designed to meet the same evidentiary standards, with endpoints including clinical remission, endoscopic response, and biomarker normalisation. Janssen's prior experience with ustekinumab in IBD provides additional regulatory and clinical development infrastructure for the guselkumab program.
Regulatory Precedent EstablishedIL-23 IBD Competitive Landscape: Key Visualisations
Comparative analysis of the selective IL-23p19 inhibitor class in IBD, covering mechanistic positioning, development stage, and competitive differentiation across guselkumab, risankizumab, and ustekinumab.
IBD Development Stage by Agent and Indication
Regulatory and clinical stage of each IL-23 class agent across Crohn's disease and ulcerative colitis indications.
Guselkumab vs. Risankizumab: Head-to-Head Profile
Direct comparison of key development and mechanistic attributes between the two selective IL-23p19 inhibitors competing in IBD.
| Attribute | Guselkumab (Tremfya) | Risankizumab (Skyrizi) |
|---|---|---|
| Target | IL-23p19 Selective | IL-23p19 Selective |
| Developer | Janssen (J&J) | AbbVie |
| CD Status | Phase III (GALAXI) | Approved Leader |
| UC Status | Phase III (GALAXI) | Phase III |
| Antibody Type | IgG1λ human mAb | IgG1 human mAb |
| IL-12 Sparing | Yes Preserved | Yes Preserved |
IL-23 Inhibitor Class: IBD Indication Coverage
Distribution of active clinical development programs across Crohn's disease and ulcerative colitis within the IL-23 inhibitor class.
GALAXI Program: Clinical Development Pathway
Sequential phases of the GALAXI Phase III program from induction through to potential regulatory submission for guselkumab in IBD.
Janssen vs. AbbVie: IL-23 IBD Patent and Clinical Strategy
The IL-23 inhibitor class in IBD is dominated by two primary assignees — Janssen (J&J) and AbbVie — with ustekinumab providing Janssen's established base and guselkumab representing its next-generation selective IL-23p19 asset.
Janssen's Dual-Asset IBD Strategy
Janssen holds a unique position in IBD as the developer of both ustekinumab (Stelara), the established dual IL-12/IL-23 inhibitor approved in both CD and UC, and guselkumab (Tremfya), the next-generation selective IL-23p19 inhibitor in Phase III. This dual-asset strategy allows Janssen to maintain market presence through ustekinumab while positioning guselkumab as a mechanistically superior successor — particularly as ustekinumab faces biosimilar competition.
AbbVie's First-Mover Advantage with Risankizumab
AbbVie's risankizumab (Skyrizi) achieved regulatory approval for Crohn's disease ahead of guselkumab, establishing a first-mover advantage in the selective IL-23p19 inhibitor class for IBD. Risankizumab's approved CD label and ongoing UC Phase III program create a high evidentiary bar that guselkumab's GALAXI program must match or exceed. The competitive IP landscape between Janssen and AbbVie in IL-23p19 inhibition spans formulation, dosing regimen, and manufacturing patents in addition to composition-of-matter protection.
IL-23 Class IBD Regulatory Status Tracker
Current regulatory and development status across the three key IL-23 pathway inhibitors in IBD, based on publicly available clinical program information.
| Agent | Developer | Crohn's Disease | Ulcerative Colitis | Mechanism | Status Signal |
|---|---|---|---|---|---|
| Guselkumab (Tremfya) | Janssen (J&J) | Phase III | Phase III | IL-23p19 selective | GALAXI Active |
| Risankizumab (Skyrizi) | AbbVie | Approved | Phase III | IL-23p19 selective | CD Leader |
| Ustekinumab (Stelara) | Janssen (J&J) | Approved | Approved | IL-12/IL-23 p40 dual | Biosimilar Pressure |
Track Guselkumab Regulatory Milestones in Real Time
PatSnap Eureka monitors patent filings, trial registrations, and regulatory submissions across the IL-23 IBD class continuously.
Guselkumab (Tremfya) in IBD — key questions answered
Guselkumab (Tremfya) is Janssen's selective IL-23p19 inhibitor under active Phase III investigation for inflammatory bowel disease, specifically Crohn's disease and ulcerative colitis, through the GALAXI clinical program. It works by selectively blocking the IL-23 pathway, which plays a central role in driving intestinal inflammation in IBD.
The GALAXI clinical program is Janssen's Phase III investigation of guselkumab in inflammatory bowel disease, covering both Crohn's disease and ulcerative colitis. The program includes multiple trials designed to evaluate clinical endpoints relevant to IBD remission and response.
Both guselkumab (Tremfya, Janssen) and risankizumab (Skyrizi, AbbVie) are selective IL-23p19 inhibitors competing in the IBD space. Risankizumab has received regulatory approval for Crohn's disease and is further along in its IBD regulatory pathway, while guselkumab remains in active Phase III investigation through the GALAXI program.
Ustekinumab (Stelara, Janssen) is a dual IL-12/IL-23 inhibitor that blocks both the p40 subunit shared by IL-12 and IL-23, whereas guselkumab selectively targets only the IL-23p19 subunit. This selective IL-23 blockade is the mechanistic basis differentiating the next-generation IL-23 inhibitors from ustekinumab.
The IL-23 inhibitor class in IBD includes guselkumab (Tremfya, Janssen) in Phase III via the GALAXI program, risankizumab (Skyrizi, AbbVie) which has received approval for Crohn's disease, and ustekinumab (Stelara, Janssen) as the established dual IL-12/IL-23 inhibitor. The competitive IP and translational landscape spans Janssen and AbbVie as the primary assignees in this therapeutic class.
Guselkumab is being studied in both Crohn's disease and ulcerative colitis through the GALAXI Phase III clinical program, making it one of the few selective IL-23p19 inhibitors with an active development program spanning both major IBD indications simultaneously.
Still have questions? Let PatSnap Eureka answer them instantly with AI-powered patent and literature search.
Ask PatSnap Eureka About GuselkumabAccelerate Your IL-23 IBD Intelligence with PatSnap Eureka
Join 18,000+ innovators already using PatSnap Eureka to track guselkumab, risankizumab, and the full IL-23 inhibitor class in real time — from patent filings to clinical milestones.
References
- U.S. Food and Drug Administration (FDA) — Regulatory guidance and approval records for IL-23 inhibitors in inflammatory bowel disease, including risankizumab (Skyrizi) Crohn's disease approval.
- European Medicines Agency (EMA) — Regulatory framework and assessment reports for biologic therapies in Crohn's disease and ulcerative colitis.
- National Institutes of Health (NIH) — Literature and clinical trial registry data on IL-23 pathway inhibition in inflammatory bowel disease, including guselkumab and the GALAXI program.
- ClinicalTrials.gov — GALAXI Phase III trial registrations for guselkumab in Crohn's disease and ulcerative colitis.
- PatSnap Innovation Intelligence Platform — Patent landscape and competitive IP analysis for the IL-23 inhibitor class in IBD, including Janssen and AbbVie assignee data.
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Clinical development status reflects publicly available information at time of publication.
PatSnap Eureka searches patents and research to answer instantly.